Results

What the flight showed

Preliminary results from the CAN-RGX 2026 parabolic flight campaign, first presented at the 77th International Astronautical Congress in Antalya, Türkiye.

Two CLOT-LESS team members on stage at the 77th International Astronautical Congress, beside the title slide of their talk.
Presented · 6 October 2026

77th International Astronautical Congress

Thrombolysis in Microgravity: A Parabolic Flight Feasibility Study Toward Autonomous Medical Care in Deep Space

An oral presentation of the platform, the flight and the first look at the data. The paper appears in the congress programme as Thrombolytic Pharmacodynamics in Microgravity: Implications for Autonomous Medical Care in Deep Space.

Paper
IAC-26,A1,3,9,x113307
Session
6 October 2026 · Hall 7
Location
Antalya, Türkiye

The flight

Two days on the NRC Falcon 20

CLOT-LESS flew out of Ottawa on 1 and 2 September 2026: nine parabolas on the first day and eleven on the second. The first day did not produce usable data, so everything below comes from the second, logged by the payload's own accelerometers and pressure sensors at 20 Hz.

  • 2

    Flight days

    1–2 September 2026

  • 11

    Parabolas analysed

    Flight day 2 · 10 paired runs

  • 22 s

    Microgravity window

    Per parabola, measured

  • 0.07 g

    Mean residual gravity

    From onboard accelerometers

How each run worked

The design is paired: on every parabola one tenecteplase (TNKase) channel and one saline channel were infused at the same time, through clots made from the same blood. Each clot pair was then infused again on the next two parabolas, to follow how its resistance changed with repeated exposure.

Each run started at zero-g onset with a short take-up phase, then infused at 150 µL/min for the rest of the microgravity window, while the pressure drop across the clot, the gravity level and video were recorded throughout. A clot blocking the channel raises the pressure needed to push fluid through it; as it dissolves or erodes, that pressure drop falls.

On the second flight day the platform worked as designed: runs started right at zero-g onset and the system logged the whole flight with no data loss.

Macro camera view of the eight clot channels during flight, each holding a dark red clot.
What the in-flight camera saw: eight channels, four perfused with tenecteplase and four with saline.

Main result

What we saw

With every repeat infusion, the clots treated with tenecteplase became noticeably easier to push fluid through, potentially signalling that they were breaking down. The matching saline controls barely changed, although due to our limited number of samples, statistical significance cannot be established.

  • TNKase channels

    Clearly loosened

    In all three clot pairs, resistance to flow fell with each infusion of the drug.

  • Saline controls

    Barely changed

    The same clots perfused with saline stayed close to where they started.

The difference held in the same direction in every pair, even after correcting for small offsets in the sensors' baselines. That is the pattern you would expect if a clot-dissolving drug keeps working in microgravity.

Preliminary

We cannot yet tell how much of the change is the drug dissolving the clot versus fluid physically wearing it away. Full results will follow in a peer-reviewed paper.

Lessons

What the flight taught us

  1. 01

    Fresh clots are stiffer than expected

    The first push into a new clot went past the range of our pressure sensors. By the second infusion the clot had loosened enough to read normally.

  2. 02

    22 seconds is enough

    The pressure reading settles within a few seconds of the pump starting, leaving most of each parabola as steady, usable signal.

  3. 03

    Vomiting is inevitable

    Don’t resist.

Conclusions

Where this leaves us

Platform
An automated, paired pressure-drop platform measured thrombolysis on every parabola.
Pharmacology
Clot resistance fell noticeably over repeat TNKase infusions and only slightly with saline, in all three pairs.
Limitations
Only three clot pairs, and the clots were not size-matched. We cannot yet separate enzymatic lysis from mechanical erosion, and the 1 g comparison is limited to one run.

Next steps

  1. 01
    Wider-range sensing

    Pressure sensors with a wider range, to capture the first push into fresh clots instead of saturating.

  2. 02
    D-dimer sampling

    D-dimer in the effluent as a biochemical marker of fibrin breakdown, alongside the pressure read-out.

  3. 03
    Glass slides

    Glass channels for better clot adherence to the walls.

Beyond thrombolysis: the same platform can test other hematologic questions in microgravity — anticoagulants, platelets and hemostatic agents.

How the platform was built → Photos from the flight and the congress →